ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Sildenafil/Viagra in the treatment of premature ejaculation
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 141088" data-attributes="member: 13851"><p><strong><span style="color: rgb(184, 49, 47)">Abstract </span></strong></p><p>The arrival of Pfizer’s blue pill Sildenafil in 1998 brought a great relief both to patient and physician signalling the start of a great era of medical therapy in sexual medicine. Since then the sexual medicine experts have been prescribing sildenafil in erectile dysfunction with acceptable minor adverse events. But the use of sildenafil in premature ejaculation (PE) is still debated. 2018 being the 20th anniversary of sildenafil, we have compiled interesting facts about the role of sildenafil in PE from various original articles, systematic reviews, meta-analyses, economic brochures and sexual medicine committee guidelines. The major issues in most of these studies were the heterogeneity in the definition of PE and estimating the exact ejaculatory latency time. This perspective article highlights the positive role of sildenafil in the management of PE (even without ED) with acceptable adverse events. Now that we have a standardised definition of PE from International Society of Sexual Medicine (ISSM) and a psychogenic component in PE definition, more randomised placebo-controlled studies are required to further establish its role.</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Conclusion</strong> </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">The evaluation and treatment of PE is complex, and guidelines for such management have recently evolved. </span>Now that we have an evidence based definition for PE from ISSM and standards in sexual dysfunction clinical trials, it’s time we start reporting randomised controlled trials using the CONSORT statement. </strong>More convenient methods of reporting IELT should be devised to avoid reporting bias. <strong><span style="color: rgb(184, 49, 47)">EAU 2018 guidelines has a “strong” recommendation for the use of sildenafil (PDE5-I) alone or in combination with other therapies in patients with PE (without ED), </span><span style="color: rgb(0, 0, 0)">although AUA and ISSM still do not recommend PDE5-I alone in PE (without ED)</span></strong><span style="color: rgb(0, 0, 0)">. </span></p></blockquote><p></p>
[QUOTE="madman, post: 141088, member: 13851"] [B][COLOR=rgb(184, 49, 47)]Abstract [/COLOR][/B] The arrival of Pfizer’s blue pill Sildenafil in 1998 brought a great relief both to patient and physician signalling the start of a great era of medical therapy in sexual medicine. Since then the sexual medicine experts have been prescribing sildenafil in erectile dysfunction with acceptable minor adverse events. But the use of sildenafil in premature ejaculation (PE) is still debated. 2018 being the 20th anniversary of sildenafil, we have compiled interesting facts about the role of sildenafil in PE from various original articles, systematic reviews, meta-analyses, economic brochures and sexual medicine committee guidelines. The major issues in most of these studies were the heterogeneity in the definition of PE and estimating the exact ejaculatory latency time. This perspective article highlights the positive role of sildenafil in the management of PE (even without ED) with acceptable adverse events. Now that we have a standardised definition of PE from International Society of Sexual Medicine (ISSM) and a psychogenic component in PE definition, more randomised placebo-controlled studies are required to further establish its role. [B]Conclusion[/B] [B][COLOR=rgb(184, 49, 47)]The evaluation and treatment of PE is complex, and guidelines for such management have recently evolved. [/COLOR]Now that we have an evidence based definition for PE from ISSM and standards in sexual dysfunction clinical trials, it’s time we start reporting randomised controlled trials using the CONSORT statement. [/B]More convenient methods of reporting IELT should be devised to avoid reporting bias. [B][COLOR=rgb(184, 49, 47)]EAU 2018 guidelines has a “strong” recommendation for the use of sildenafil (PDE5-I) alone or in combination with other therapies in patients with PE (without ED), [/COLOR][COLOR=rgb(0, 0, 0)]although AUA and ISSM still do not recommend PDE5-I alone in PE (without ED)[/COLOR][/B][COLOR=rgb(0, 0, 0)]. [/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Sildenafil/Viagra in the treatment of premature ejaculation
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top